Close

Clinical Pharmacogenetics Implementation Consortium

Clinical Pharmacogenetics Implementation Consortium

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Teri E. Klein, Ph.D.
Stanford University

Co-Investigator
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital

Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University

Steering Committee

Teri E. Klein, Ph.D.
Stanford University

Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Michelle Whirl-Carrillo, Ph.D.
Stanford University

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

Dan M. Roden, M.D.
Vanderbilt University

Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH

Larisa Cavallari, Pharm.D.
University of Florida

Stuart A. Scott, Ph.D.
Stanford University and Stanford Healthcare

Sara Van Driest, M.D., Ph.D.
Vanderbilt University

Scientific Advisory Board

Julie A. Johnson, Pharm.D.
University of Florida

Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories

Robert Nussbaum, M.D.
University of California, San Francisco

Heidi Rehm, Ph.D.
Partners Healthcare

Marc S. Williams, M.D.
Geisinger

Sandy Aronson
Partners Personalized Medicine

Justin B. Starren, M.D., Ph.D.
Northwestern University

Houda Hachad, Pharm.D., M. Res.
AccessDx/Medtek21

Andrea Gaedigk, Ph.D.
Children’s Mercy

News & Announcements

  • The latest round of PharmGKB’s pediatric drug summaries is now live on PharmGKB pediatric. This release includes summaries for 55 drugs, bringing the total summary count to over 180, now including all drugs on the Best Pharmaceuticals for Children Act (BPCA) priority list in addition to all CPIC guideline drugs.Drugs with new summaries include:AlfentanilAmiodaroneAmpicillinAzithromycinBosentanCidofovirCiprofloxacinClindamycinClonidineDexmedetomidineDigoxinDoxycyclineFurosemideGranisetronGriseofulvinHeparinHydralazineHydrochlorothiazideHydromorphoneHydroxycobalaminHydroxyureaIsotretinoinLabetalolLevofloxacinLevothyroxineLidocaineLisinoprilLithiumLorazepamLurasidoneMeropenemMetforminMethylprednisoloneMidazolamMolindoneNafcillinNicardipineNifedipineNifurtimoxOlanzapinePentobarbitalPiperacillin-TazobactamPralidoximePrednisoloneSertralineSildenafilSpironolactoneTerbutalineTimololTopiramateTranexamic AcidValganciclovirVancomycinVecuronium
  • On May 2nd, the American Academy of Pediatrics (AAP) released a pre-published policy statement titled “Eliminating Race-Based Medicine,” noting that race is a “historically derived social construct that has no place as a biologic proxy.” The statement provides necessary and meaningful commentary on “the medical field’s history of inaccurate applications of race correction and adjustment […]
  • We are holding an Ask a Curator zoom targeted towards healthcare professionals wanting to learn more about PharmGKB and pharmacogenomics. This is part of NHGRI’s Healthcare Professionals Genomics Education Week (#MedGeneEd22). Be sure to spread the word to colleagues who may find this useful.We are asking people to please register in advance with their questions […]
  • A Haiku about PGx for National Poetry Month.Diagnosed star one,Yet severe toxicity.What did the lab test?What does *1 really mean? And why does that matter?The star alleles of the drug metabolizing enzyme genes are an unusual way of defining variation and are perhaps one of the most misunderstood aspects of pharmacogenomics. Arising from attempts to […]
  • The third round of PharmGKB's pediatric drug summaries is now live on PharmGKB pediatric. This release includes over 20 additional drugs with a focus on those on the Best Pharmaceuticals for Children Act (BPCA) priority list, including:AlbendazoleAmphotericin bArtesunateAtropineBaclofenBenznidazoleBetamethasoneCanakinumabCefepimeCeftazidimeChlorproguanilCortisone acetateDopamineEltrombopagEpinephrineEtomidateFosfomycinGlycopyrrolateMontelukastNevirapineRitonavirThese pediatric drug summaries contain key information relevant to prenatal, postnatal, and pediatric populations, manually curated from […]

Follow @cpicpgx on Twitter